Skip to main content

Table 4 Nine potential risk factors were considered the association with incidence of HIV-1 DRMs among participants experiencing treatment failure

From: Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China

VariableMutation identified (n = 914)No mutations identified (n = 1381)ORP95%CI
Gender
 Male6549940.950.680.76–1.20
 Female2603871  
Age
  < 1420121  
 15~291462240.220.320.11–4.37
 30~443144610.210.310.01–4.22
 45~592553740.180.260.01–3.61
  ≥ 601793100.200.300.01–4.06
Regimen
 AZT + 3TC + NVP/EFV4684241  
 D4T + 3TC + NVP/EFV102621.390.100.94–2.05
 TDF + 3TC + NVP/EFV2873960.400.000.32–0.51
 Second line regimens574990.080.000.06–0.11
Subtype
 AE6078661  
 BC1262850.620.000.48–0.81
 B1031600.800.160.59–1.09
 C36451.180.550.69–2.00
 Other42251.360.280.77–2.39
CD4 abs count (cells/mm3)
  ≤ 2006857053.160.002.55–3.91
  > 20022967611.00 
WHO Stage
 I4496951  
 II2373580.90.410.70–1.16
 III1292140.810.200.59–1.12
 IV991141.080.680.74–1.59
Route of transmission
 BLOOD transmission12181  
 PWID791481.020.960.42–2.50
 MSM901281.440.430.58–3.58
 Heterosexual67610241.270.580.55–2.95
 Vertical transmission21130.490.640.02–9.80
 Unknown36501.320.580.50–3.49
Recently 7 days number of doses missed
 03698661  
  ≥ 15455152.940.002.38–3.63
Symptoms in recent three months
 No  1  
 Yes  1.480.001.18–1.85
  1. Note: OR Odds ratio;
  2. CI Confidence interval
  3. P-Values in bold are statistically significant at the 0.05 significance level